, they found that the response in the early phase of the trial, could predict the therapeutic benefit after a follow-up of six months ( Good candidates for eluxadoline (second-line) Women and men with moderate IBS-D, and both abdominal pain and diarrhea as predominant symptoms, after loperamide failure and without any contraindication (cholecystectomy, biliary duct obstruction, pancreatitis, hepatic impairment, alcohol abuse, and chronic or severe constipation)
In spring 2024, Pulmuone launched two flavors, chocolate brownie and strawberry raspberry, using its patent-pending air softening formulation
Some solutions are already being developed to complement GLP-1 treatments, and this signals a third wave of innovation he noted
To further validate the screening results, we selected an enriched target, Notch1